Abstract
Cardiovascular diseases (CVD) are the major cause of death worldwide. The identification of markers able to detect the early stages of such diseases and/or their progression is fundamental in order to adopt the best actions in order to reduce the worsening of clinical condition. Brain natriuretic peptide (BNP) and NT-proBNP are the best known markers of heart failure (HF), while troponins ameliorated the diagnosis of acute and chronic coronary artery diseases. Nevertheless, many limitations reduce their accuracy. Physicians have tried to develop further detectable molecules in order to improve the detection of the early moments of CVD and prevent their development. Soluble ST2 (suppression of tumorigenicity 2) is a blood protein confirmed to act as a decoy receptor for interleukin-33. It seems to be markedly induced in mechanically overloaded cardiac myocytes. Thus, HF onset or worsening of a previous chronic HF status, myocardial infarct able to induce scars that make the myocardium unable to stretch well, etc, are all conditions that could be detected by measuring blood levels of soluble ST2. The aim of this review is to explore the possible role of ST2 derived-protein as an early marker of cardiovascular diseases, above all in heart failure and ischemic heart diseases.
Highlights
Cardiovascular diseases (CVD) are the main leading cause of death worldwide [1]
The aim of this review is to explore the possible role of ST2 derived-protein as an early marker of cardiovascular diseases, above all in heart failure and ischemic heart diseases
Socrates et al outlined that the subgroup of patients with high sST2 levels and low levels of natriuretic peptides had increased mortality risk [29]
Summary
Cardiovascular diseases (CVD) are the main leading cause of death worldwide [1]. Their incidence is still increasing, even in developing countries [2] and it greatly diminishes individuals’ quality of life and survival rates.Primary and secondary preventive actions are required in order to arrest the negative development of CVD. Cardiovascular diseases (CVD) are the main leading cause of death worldwide [1]. Their incidence is still increasing, even in developing countries [2] and it greatly diminishes individuals’ quality of life and survival rates. Primary and secondary preventive actions are required in order to arrest the negative development of CVD. Physicians are involved in searching for tools able to detect the early moments of CVD development. Markers of CVD will allow immediate interventions in order to prevent the beginning of the diseases or, at least, minimize their negative consequences. Biochemical markers work side by side with the latter ultrasonographic tools in order to detect early alterations of cardiovascular system. Ciccone et al [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
